Psychometric properties and diagnostic criteria of Negative Symptoms Assessment-5 (NSA-5) in schizophrenia
https://doi.org/10.31363/2313-7053-2020-1-83-92
Abstract
The Negative Symptoms Assessment-5 (NSA-5) is clinical assessment tool for measuring the severity of negative symptoms that reflects the modern concept of negative syndrome. The purpose of this study was to conduct a comprehensive psychometric analysis of the Russian-language version of the NSA-5 with the determination of diagnostic criteria for assessing the severity of negative symptoms in the dynamics of treatment in patients with schizophrenia. Psychometric analysis was done on the base of the Rush measurement. Minimum clinically important differences were found using the MDC95% index for each score of the scale. The NSA-5 showed the adequate construct validity of its diagnostic points, the unidimensionality of the structure, high reliability and sensitivity to changes. The scale is able to differentiate 7 metric levels of severity of negative symptoms, diagnostic criteria are suitable for use in clinical practice and scientific research.
References
1. Assanovich MA. The method of defining cut-off criteria in clinical rating scales developed using Rasch model. Zhurnal psikhiatrii i psikhofarmakoterapii im. P. B. Gannushkina. 2017; 18(3):19–24. (In Russ.).
2. Assanovich MA. The problem of scientific measurement in psychodiagnostics. Zhurnal GrGMU. 2014; 45: 9–14. (In Russ.).
3. Assanovich MV. Сlinical evaluation scales of the negative syndrome of schizophrenia. Zhurnal GrGMU. 2017; 1(57):27– 31. (In Russ.).
4. Smirnova DA. Negative symptoms in schizophrenia in a focus of researcher, clinician and patient. Zhurnal psikhiatrii i psikhofarmakoterapii im. P.B. Gannushkina. 2014; 2:7–18. (In Russ.).
5. Alphs L., Szegedi A., Cazorla P., Morlock R., Coon C., Van Willigenburg A., Panagides J. The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training. Psychiatry. 2010; 7(7):26–32.
6. Blanchard J.J., Kring A.M., Horan W.P. Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophrenia Bulletin. 2011; 37:291–299. doi:10.1093/schbul/sbq104
7. Boone W.J. Rasch Analysis for Instrument Development: Why, When, and How? CBE life sciences education. 2016; 15(4):41–47. doi: 10.1187/cbe.16-04-0148
8. Eisen S.V., Ranganathan G., Seal P., Spiro A. Measuring clinically meaningful change following mental health treatment. The J. of Behav. Health Services & Research. 2007; 34(3):272–289. doi: 10.1007/s11414-007-9066-2
9. Galderisi S., Mucci A., Buchanan R. W., Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. The Lancet Psychiatry. 2018; 5(8):1–14. doi: 10.1016/S2215-0366(18)30050-6
10. Garcia-Portilla M.P., Garcia-Alvarez L., Saiz P.A., Al-Halabi S., Bobes-Bascaran M.T., Bascaran M.T. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neu-rosci. 2015; 265(7):559–566. doi:10.1007/s00406-015-0595-z
11. Horan W.P., Kring A. M., Gur R.E., Reise S.P., Blanchard J. J. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophrenia Research. 2011; 132:140–145. doi: 10.1016/j.schres.2011.06.030
12. Kirkpatrick B., Fenton W. S., Carpenter W.T., Marder S. R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin. — 2006; 32:296–303. doi: 10.1093/schbul/sbj053
13. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S. R. The Brief Negative Symptom Scale: Psychometric Properties Schizophrenia Bulletin. 2011; 37(2):300–305. doi: 10.1093/schbul/sbq059
14. Kring A.M., Gur R.E., Blanchard J.J., Horan W.P., Reise S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation. Am J Psychiatry. 2013; 170(2):165– 172. doi: 10.1176/appi.ajp.2012.12010109
15. Marder S.R., Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017; 16:14–24. doi: 10.1002/wps.20385
16. Rai S.K., Yazdany J., Fortin P.R., Aviña-Zubieta J. A. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis research & therapy. 2015; 17(1):143–151. doi: 10.1186/s13075-015-0658-6
Review
For citations:
Assanovich M.V. Psychometric properties and diagnostic criteria of Negative Symptoms Assessment-5 (NSA-5) in schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2020;(1):83-92. (In Russ.) https://doi.org/10.31363/2313-7053-2020-1-83-92
Views:
1298
Email this article 